Breast Surgeons Advise All Breast Cancer Patients Be Offered Genetic Testing
Executive Summary
The American Society of Breast Surgeons published new guidelines, recommending that genetic testing should be made available to all patients with a history of breast cancer. The new recommendations are not in line with existing guidelines made by the National Comprehensive Cancer Network.
You may also be interested in...
Market Intel: Breast Imaging Market Driven By AI, Technological Innovation
The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.
Diagnostic Companies Rush To Test Formerly Off-Limit Genes
Although Myriad says the Supreme Court’s recent ruling that isolated genes can’t be patented does not leave its BRCA1 and BRCA2 assays unprotected, other diagnostic companies are now incorporating the genes into their tests for the likelihood of inheriting cancer at a fraction of the previous cost.
Mosie Baby First To Win FDA Clearance For At-Home DYI Artificial Insemination Kit
Austin-based start-up Mosie received FDA clearance for a home insemination kit to help people get pregnant. The kit retails for $129.99.